Moleculin Biotech MBRX Initiated with 'Sell' Rating by StockNews.com Analysts

On Monday, research analysts at StockNews.com started coverage on shares of Moleculin Biotech, Inc. MBRX, a Houston-based clinical-stage pharmaceutical company. In their introductory report, the brokerage house assigned a 'sell' rating to the company's stock, signaling caution to potential investors. StockNews.com's analysis follows Moleculin Biotech's efforts to develop novel treatments for resistant viruses and cancers.

Moleculin Biotech's Stock Performance

Trading of Moleculin Biotech MBRX commenced the week at $0.54. Noteworthy is the company's fifty-day simple moving average, recorded at $0.47, while the 200-day simple moving average stands at $0.57. Moleculin Biotech has experienced a low of $0.34 and a peak of $1.65 over the past twelve months, reflecting the volatile nature of biotech investments. The company currently holds a market capitalization of approximately $16.10 million and exhibits a price-to-earnings ratio of -0.53, alongside a beta of 1.89 that hints at its relative volatility in the stock market.

The latest earnings report from Moleculin Biotech MBRX revealed a quarterly EPS of ($0.20), outperforming the consensus estimates by analysts which projected an EPS of ($0.28). This marked an improvement compared to the prior year's EPS of ($0.24) for the same quarter. Forecasts suggest that Moleculin Biotech may post an EPS of -$0.94 for the current fiscal year.

Investor Movements and Institutional Holdings

Recent months have seen a flurry of activity from institutional investors and hedge funds in Moleculin Biotech's shares. Charles Schwab Investment Management Inc. took on a new position in the company during the fourth quarter, valued at some $39,000. Renaissance Technologies LLC augmented its holdings by 34.7% in the second quarter, now owning 127,400 shares valued at $74,000. Additionally, State Street Corporation STT—a global financial services provider—raised its stake by 19.2% in the first quarter, resulting in the possession of 71,397 shares, valued at $127,000. Institutional investors, including the likes of hedge funds, currently own 7.67% of Moleculin Biotech's stock.

About Moleculin Biotech

Moleculin Biotech, Inc. MBRX is actively engaged in the clinical development of innovative pharmaceutical agents aimed at the treatment of life-threatening cancers and viruses. Their lead drug candidate, Annamycin, is undergoing Phase 1/2 studies for tackling relapsed or refractory acute myeloid leukemia (AML) as well as other lung-metastasized cancers.

Moleculin, Biotech, Analyst